Test For Named Disease, Body Condition Or Organ Function Patents (Class 436/811)
  • Patent number: 7781169
    Abstract: Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: August 24, 2010
    Inventors: Mats Paulsson, Uwe Odenthal, Neil Smyth, Daniel Aeschlimann, Sarolta Karpati, Miklos Sardy
  • Patent number: 7780831
    Abstract: Methods of analyzing the electrophoretic mobility distribution of von Willebrand factor (vWF) multimers include providing a sample medium comprising a plurality vWF multimers. The vWF multimers are electrophoretically separated by electrohoretic mobility in the sample medium by subjecting said sample medium to an electric field to provide separated vWF multimers. The separated vWF multimers in the sample medium are exposed to a light source to produce scattered light. The scattered light is detected, and the electrophoretic mobility distribution of the separated vWF multimers is determined from the detected scattered light.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: August 24, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Don A. Gabriel
  • Patent number: 7772011
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 10, 2010
    Inventors: Ronald Joseph Harbeck, Karen Mary Andrews, Donald MacGlashan, Jr.
  • Patent number: 7771954
    Abstract: A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: August 10, 2010
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang
  • Patent number: 7767419
    Abstract: The invention provides a method to efficiently express high levels of a recombinant untagged NT-proBNP for use as a calibrator in NT-proBNP immunoassays.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 3, 2010
    Assignee: Nexus DX, Inc.
    Inventors: Azhar Alvi, William Yajima, Roshana Sikora, George Jackowski, Mee-Ra Hong
  • Patent number: 7767393
    Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: August 3, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Mark A. Rubin, Arun Sreekumar
  • Patent number: 7754436
    Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using a anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: July 13, 2010
    Assignee: Electrophorectics Limited
    Inventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmerman
  • Patent number: 7732145
    Abstract: A rapid immunoassay method and apparatus for detecting foot and mouth disease virus are disclosed. The method and test device permit pen-side testing of animals and provide test results within a relatively short time period. In a preferred embodiment, the method and apparatus provide a means for differentiating between FMDV-infected and FMDV-vaccinated animals.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: June 8, 2010
    Assignees: Princeton Biomeditech Corporation, Republic of Korea (National Veterinary Research & Quarantine Service)
    Inventors: Je-Mo Kang, Nam-Kyu Shin, In-Soo Cho, Bang-Hun Hyun, Kwang-Nyeong Lee, Jae-Ku Oem, Soo-Jeong Kye, Young-Joon Ko, Bok-Kyung Ku, Soo-Hwan An, In-Joong Kim, Ok-Kyung Kim, Hee-Jong Kim, Ki-Yong Jang, Suh-Ha Hwang, Chang-Ho Kim, Song-Woo Ko, Yi-Seok Joo
  • Patent number: 7723059
    Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: May 25, 2010
    Assignee: Biosite Incorporated
    Inventors: Kenneth F. Buechler, Paul H. McPherson
  • Patent number: 7723124
    Abstract: More particularly, the present invention relates to a method for the detection of a target, e.g. pathogen in a human body fluid wherein a body fluid sample is collected with a swab member.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: May 25, 2010
    Assignee: Rapid Pathogen Screening, Inc.
    Inventors: Franz Aberl, Marcus Scheibenzuber, Robert F. Sambursky, Robert W. Vandine, Jose S. Sambursky
  • Patent number: 7722858
    Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 25, 2010
    Assignees: Board of Trustees of the University of Arkansas, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Sudhir V. Shah, Alexei G. Basnakian, Yousri M. Barri
  • Patent number: 7718386
    Abstract: Assays for the detection of diabetes and prediabetic status rely on exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64kD autoantigen present on pancreatic ?-cells. The purified ligand is usually purified glutamic acid decarboxylase (GAD) or a fragment or analog thereof. Preferably, the assays will detect the presence of antibodies to both lower molecular weight GAD and higher molecular weight GAD since diabetic and prediabetic status may be associated with only one of these two forms. The assays can be performed using conventional protocols, such as radioimmunoassay, enzyme-linked immunosorbent assay, and enzyme assay. Methods for treating diabetes comprise administering pharmaceutical compositions including the purified ligand, particularly when coupled to an immunoglobulin or lymphoid cell to induce tolerance.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 18, 2010
    Assignees: The Regents of the University of California, Yale University
    Inventors: Steinunn Baekkeskov, Henk-Jan Aanstoot, Pietro Decamilli, Franco Folli, Michele Solimena
  • Patent number: 7709272
    Abstract: The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: May 4, 2010
    Assignee: N-Dia, Inc.
    Inventors: Boris Fuks, Dmitrii D. Petrunin, Evgeny I. Zaraisky, Marina N. Boltovskaya, Svetlana V. Nazimova, Nelly A. Starosvetskaya, Alexandr Konstantinov, Margarita I. Marshiskaia
  • Patent number: 7700309
    Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-? peptide (x-?41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A?(x-?41) and tau. Low levels of A?(x-?41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A?(x-?41) and low levels of tau are a negative indication of Alzheimer's disease.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: April 20, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Peter A. Seubert, Carmen Vigo-Pelfrey, Dale B. Shenk, Robin Barbour
  • Patent number: 7695972
    Abstract: Method for the in vitro diagnostic or for the monitoring of a disease involving an inflammatory reaction within a patient, which comprises the steps of: a) providing a biological sample from the patient; b) measuring the amount of selenoprotein P which is contained in the biological sample; c) comparing the amount of selenoprotein P measured at step b) i) with the amount of selenoprotein P which is contained in a biological sample from an individual which is not affected with the disease; or ii) with the amount of selenoprotein P which was contained in a biological sample from the same patient.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: April 13, 2010
    Inventor: Xavier Forceville
  • Patent number: 7691640
    Abstract: A biochemical marker for the diagnosis of a central nervous system leukodystrophic genetic disorder, e.g., Childhood Onset Ataxia and Central Nervous System Hypomyelination (CACH)/Vanishing White Matter Disease (VWM) has been discovered herein. Such a marker has been found in the cerebrospinal fluid (CSF) of such patients. A two dimensional gel electrophoresis/mass spectrometry or image analysis of stained transferrin isoforms approach revealed that patients with CACH/VWM have a pronounced deficiency of the basic asialo form of the transferrin compared to the amounts of asialotransferrin normally present in CSF from healthy controls or other CNS disorders. The acidic sialotransferrin isoform is not reduced in these disorders. The transferrin isoform abnormality described in the CSF of patients with CACH/VWM is unique and may be used as a clinical diagnostic biomarker. The rapid (48 hr) and efficient diagnosis of this disorder described herein will have great clinical utility.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: April 6, 2010
    Inventors: Adeline Vanderver, Yetrib Mathout
  • Patent number: 7659075
    Abstract: Method for early differential diagnosis and detection, for prognosis and assessment of the severity and for therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections, in which, preferably with additional determination of at least one further parameter suitable for sepsis diagnosis, the amount of soluble cytokeratin fragments, in particular of CYFRA 21-1, TPS, TPA and/or sCY1F, in a biological fluid of a patient in whom a sepsis is present or a sepsis is suspected is determined and conclusions with regard to the presence, the expected course, the severity and/or the success of initiated measures for the therapy of the sepsis are drawn from the determined amount of soluble cytokeratin fragments.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: February 9, 2010
    Assignee: B.R.A.H.M.S Aktiengesellschaft
    Inventor: Andreas Bergmann
  • Patent number: 7655480
    Abstract: The present invention in one embodiment is an early detection marker for chronic or acute inflammatory-associated diseases. Chronic diseases may include atherosclerosis, Alzheimer's disease, asthma, rheumatoid arthritis, osteoarthritis, and inflammatory diseases of the bowel such as Crohn's disease, Ulcerative colitis, Irritable bowel syndrome and Inflammatory bowel disease. Acute diseases may include sepsis, acute systemic infections, acute lung injury, and acute respiratory distress syndrome.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: February 2, 2010
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: H. Anne Pereira
  • Patent number: 7648825
    Abstract: Biomarkers that are diagnostic of type 1 diabetes, type 2 diabetes and/or diabetic disorder are identified. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of type 1 diabetes, type 2 diabetes and/or diabetic disorder. An analysis includes the parameters of matching for BMI and Tanner stage. Receiver-operator characteristic (ROC) curves were established to assess association of the biomarkers with a disease.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: January 19, 2010
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Tamir M. Ellis, Alba Esther Morales, Mark A. Atkinson, Clive H. Wasserfall
  • Patent number: 7645616
    Abstract: Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: January 12, 2010
    Assignee: The University of Hong Kong
    Inventors: Aimin Xu, Yu Wang, Karen Siu Ling Lam
  • Patent number: 7611855
    Abstract: Using two types of antibodies, i.e., a first antibody having a higher affinity for a target substance than for a competitive substance and a second antibody having a higher affinity for the competitive substance than for the target substance, a specimen is treated with these two antibodies. Then, the competitive substance in the specimen first binds to the second antibody and thus the ratio of the target substance to the competitive substance in the specimen is enlarged. As a result, the target substance becomes liable to bind to the first antibody and, in its turn, the reactivity of the target substance is elevated compared with the case of using the first antibody alone. Thus, the target substance in the specimen can be accurately assayed while avoiding the effects of the competitive substance contained in the specimen.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: November 3, 2009
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Fumio Nomura, Takeshi Tomonaga, Katsuhiro Katayama
  • Patent number: 7611910
    Abstract: The invention relates to a method of treating Alzheimer's disease in a mammal comprising administering to the mammal an anti-microbial agent having anti-Chlamydia pneumoniae activity. The invention also relates to a method of diagnosing Alzheimer's disease in a mammal comprising measuring the serum anti-Chlamydia pneumoniae antibody titer in a patient suspected of having Alzheimer's disease.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: November 3, 2009
    Assignee: Intracell, LLC
    Inventors: Brian J. Balin, J. Todd Abrams, Alan P. Hudson, Judith A. Whittum-Hudson
  • Patent number: 7608414
    Abstract: Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: October 27, 2009
    Assignee: Glycominds, Ltd
    Inventors: Nir Dotan, Avinoam Dukler, Rom T. Altstock
  • Patent number: 7604946
    Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Disclosed is a stabilized composition of troponin; the stabilized composition can comprise a stabilized composition of troponin I, wherein the troponin I is oxidized, the troponin I can be unbound or the troponin I can be in a complex.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: October 20, 2009
    Assignee: Biosite Incorporated
    Inventors: Kenneth F. Buechler, Paul H. McPherson
  • Patent number: 7604957
    Abstract: A method for food sensitivity panel testing (for sensitivities other than gluten sensitivity) by detecting IgA antibodies in serum is disclosed. A method for testing stool samples for the presence of particular antibodies, which is more sensitive and less invasive than prior art testing methods, is also disclosed for diagnosing immunologic food sensitivities. These methods of diagnosis may be used alone or in combination to further enhance the accuracy of diagnosis.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 20, 2009
    Inventor: Kenneth D. Fine
  • Patent number: 7605003
    Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: October 20, 2009
    Assignees: The Johns Hopkins University, Vermillion, Inc.
    Inventors: Daniel W. Chan, Zhen Zhang, Eric Fung, Xiao-Ying Meng
  • Patent number: 7592150
    Abstract: Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: September 22, 2009
    Assignee: Glycominds, Ltd
    Inventors: Nir Dotan, Avinoam Dukler
  • Patent number: 7588905
    Abstract: A method for identifying or monitoring SLE in an individual is provided. The method includes quantitating complement component C4d on the surfaces of platelets and comparing the amounts of C4d to reference levels of C4d on platelets of individuals without SLE and/or on platelets of the individual obtained at a different time. Kits for use in the above-described methods are provided along with computer readable media tangibly embodying executable instructions to perform the methods.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: September 15, 2009
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Jeannine Navratil
  • Patent number: 7585640
    Abstract: The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: September 8, 2009
    Assignee: University of Pittsburgh
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Chau-Ching Liu
  • Patent number: 7575939
    Abstract: Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: August 18, 2009
    Assignee: SRU Biosystems, Inc.
    Inventors: Brian T. Cunningham, Jane Pepper, Bo Lin, Peter Li, Homer Pien, Jean Qiu
  • Patent number: 7560290
    Abstract: The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: July 14, 2009
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Detlef Kozian, Stefan Schaefer, Bernward Schoelkens, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace
  • Patent number: 7547553
    Abstract: An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: June 16, 2009
    Assignee: B.R.A.H.M.S. Aktiengesellschaft
    Inventors: Andreas Bergmann, Andrea Ernst, Harald Hampel
  • Patent number: 7544513
    Abstract: The present invention provides an assay, suitable for neonatal screening of hemoglobinopathies by quantitatively determining the presence of at least one pair of hemoglobin (Hb) variants, determining the ratio between the signals obtained from each variant; and, based on that ratio, determining whether the tested subject is afflicted or not.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: June 9, 2009
    Assignee: Wallac Oy
    Inventors: Kaj Blomberg, Pasi Kankaanpaa, Thomas Campbell
  • Patent number: 7537900
    Abstract: Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: May 26, 2009
    Assignee: Glycominds Ltd.
    Inventors: Nir Dotan, Avinoam Dukler, Mikael Schwarz, Ari Gargir
  • Patent number: 7527938
    Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: May 5, 2009
    Assignee: R.E.D. Laboratories N.V./S.A.
    Inventors: Marc Fremont, Patrick Englebienne, C. V. Taylor Herst
  • Patent number: 7527939
    Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: May 5, 2009
    Assignee: Nanogen, Inc.
    Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
  • Patent number: 7527932
    Abstract: An individual's risk profile for developing a cardiovascular disorder or for experiencing a cardiovascular event is determined by 1) measuring levels of certain stress-evoked proteins including heat shock proteins (HSPs), cytokines, adhesion molecules, chemokines, and the like, or titers of the antibodies targeted to them, or 2) determining the number of seropositive responses to a group of pathogens that have been associated with the presence of atherosclerosis and/or clinical events related to atherosclerosis. The measured levels are compared with clinically derived standards that define the association of these markers with cardiovascular disease. These markers are independent of traditionally recognized risk factors.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: May 5, 2009
    Assignee: MedStar Research Institute, Inc.
    Inventors: Stephen E. Epstein, Juanhui Zhu
  • Patent number: 7524681
    Abstract: The present invention relates to a method for determining the condition of a biological fluid by recording the IR spectrum of a sample of the biological fluid. To this end, the biological fluid can be examined in its native form. The method of the invention is usable, for example, for detecting pathological conditions in organisms.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: April 28, 2009
    Inventors: Andreas Wolf, Ralf Masuch, Robert Seidel
  • Patent number: 7517648
    Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP5 protein (nephrocystin-5) and nucleic acids encoding the NPHP5 protein. The present invention also provides assays for the detection of NPHP5 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 14, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: Friedhelm Hildebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop
  • Patent number: 7510880
    Abstract: A method for determination of at least one of the lipid species in a biological sample comprising subjecting the sample to lipid extraction to obtain a lipid extract and subjecting the resulting lipid extract to multidimensional electrospray ionization mass spectrometry using either precursor ion or neutral loss scanning (or both) of all naturally occurring aliphatic chains, lipid fragments and precursor ions leading to observed fragments to generate a multidimensional matrix whose contour densities provides structural and quantitative information directly without chromatography. A method for determination of lipid content and/or lipid molecular species composition and quantity directly from lipid extracts of a biological sample comprising subjecting said lipid extract to electrospray ionization multidimensional mass spectrometry by comparisons to standards and algorithms described herein.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: March 31, 2009
    Inventors: Richard W. Gross, Xianlin Han
  • Patent number: 7507550
    Abstract: The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: March 24, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Juergen Spinke, Alfons Nichtl, Volker Klemt, Klaus Hallermayer, Michael Grol, Anneliese Borgya, Andreas Gallusser
  • Patent number: 7482135
    Abstract: A method for determining whether a urine sample has been obtained from a subject suffering from a kidney disorder involving kidney damage. The method is based on determining the level of a proteolytic enzyme in urine from the subject. Sample and optionally comparing this level with a reference value. The proteolytic enzyme preferably is a matrix metalloproteases, in particular MMP-2 or MMP-9. The method is particularly suitable for subjects with a condition or disorder that is associated with an increased risk of kidney disorders, such as diabetes. The method may adavnatageously be applied for early detection of kidney damage, in particular when the subject does not yet show any sign of microalbuminuria. The method may also be applied to a subject undergoing dialysis for determining whether the subject is suffering from remodelling of the peritoneal membrane. Thus, the method is particularly suited for patients undergoing continuous ambulatory peritoneal dialysis.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: January 27, 2009
    Assignees: Nederlandse Organisatie Voor Toegepast, Natuurwetenschappelijk Onderzoek Tno Leids Universitair Medisch Centrum
    Inventors: Johan Hendrikus Verheijen, Jan Roeland Occo Hanemaaijer, Michaela Diamant
  • Patent number: 7482174
    Abstract: The invention relates to methods of diagnosing early stages of atherosclerosis.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: January 27, 2009
    Assignee: University of Massachusetts
    Inventors: Charles R. Kiefer, L. Michael Snyder, James B. McKenney, Jane F. Trainor
  • Patent number: 7476551
    Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: January 13, 2009
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Yousri M. Barri, Sudhir V. Shah, Alexei G. Basnakian
  • Patent number: 7473564
    Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: January 6, 2009
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale
    Inventors: Philipp Lassalle, David Bechard, André-Bernard Tonnel
  • Patent number: 7473760
    Abstract: A cyclic peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, m, n and p are as defined. Further provided are compositions for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Routes of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: January 6, 2009
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Wei Yang
  • Patent number: 7455980
    Abstract: The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: November 25, 2008
    Assignee: Luminex Corporation
    Inventors: James P. Mapes, James W. Jacobson, Harold N. Baker, Michael D. Spain
  • Patent number: 7439026
    Abstract: Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: October 21, 2008
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Murugan R. Pandian, Julie Y. Lu
  • Patent number: 7427490
    Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: September 23, 2008
    Assignee: Biosite Incorporated
    Inventors: Gunars E. Valkirs, Jeffrey R. Dahlen, Howard J. Kirchick, Kenneth F. Buechler
  • Patent number: 7424437
    Abstract: A secure medical records maintenance system and associated removable memory storage device referred to as a “personal health card” for accessing the system. The secure medical records maintenance system includes a first remote server that stores patient identification information associated with multiple patents, and a second remote server that stores patient medical data associated with the multiple patents. The medical data maintained on the second remote server cannot be correlated to the associated patient identification information maintained on the first remote server based on the information contained in the first and second remote servers. To permit correlation of the files, the personal health card stores correlation information sufficient to uniquely associate a patient's patient identification information stored on the first remote computer server with that patient's medical data stored on the second remote server.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: September 9, 2008
    Assignee: Lifenexus, Inc.
    Inventors: Christopher T. Maus, Craig A. Coad, Jackson B. Connolly, Noah M. Coad, James L. Moody, Kenn A. Nesbitt, Kenneth D. Clegg